Reply to vitamin D status may explain racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era
Year: 2016
Type: letter
Abstract: We appreciate the thoughtful comments by Grant et al on vitamin D status as a possible etiology for the observed racial disparity in survival between African American and white patients with advanced renal cell carcinoma in our analysis.1 Although the National Cancer Database is a powerful tool for performing disparity and outcomes research, it has limitations and specifically does not include information on serum 25-hydroxyvitamin D levels, so we were unable to include 25-hydroxyvitamin D as a covariate in our analysis. Although interesting, the potential causative relationship between 25-hydroxyvitamin D levels and the survival difference observed between African American and white patients with advanced renal cell carcinoma remains speculative, and we are in agreement that further research should prospectively explore this possibility. No specific funding was disclosed. Matthew I. Milowsky reports clinical trials for Mirati Therapeutics, Pfizer, Cerulean Pharma, Merck, Seattle Genetics, Acerta Pharma, BioClin Therapeutics, and Roche/Genentech outside the submitted work. Tracy L. Rose, MD, MPH Matthew I. Milowsky, MD Division of Hematology/Oncology Department of Medicine University of North Carolina Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina
Source: Cancer
DOI: 10.1002/cncr.30343
Authors: Tracy L. Rose, Matthew I. Milowsky
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2519117805